Patents by Inventor Suxing Liu

Suxing Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12187684
    Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: January 7, 2025
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Yinfa Yan, Minsheng Zhang, Dong Liu, Fengqi Zhang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Publication number: 20240299360
    Abstract: Compounds of formula (I) useful as inhibitors of ADAMTS-5 and/or ADAMTS-4, pharmaceutical compositions thereof, and use of them as therapeutic agents for the treatment of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthrosis and/or rheumatoid arthritis, are disclosed.
    Type: Application
    Filed: February 3, 2021
    Publication date: September 12, 2024
    Inventors: Dong Liu, Peng Zhao, Jian Liu, Linghang Zhuang, Fengqi Zhang, Xinzhu Zhang, Chunying Song, Suxing Liu, Jing Li
  • Publication number: 20230130361
    Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.
    Type: Application
    Filed: November 21, 2022
    Publication date: April 27, 2023
    Inventors: Yinfa Yan, Minsheng Zhang, Dong Liu, Fengqi Zhang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Patent number: 11512055
    Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: November 29, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Yinfa Yan, Minsheng Zhang, Dong Liu, Fengqi Zhang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Publication number: 20220213086
    Abstract: This application discloses azole compounds of formula (I) useful as IRAK inhibitors and therapeutic agents for treatment of IRAK, especially IRAK-4, mediated disease or disorders, including autoimmune diseases, cancers, neurodegenerative disorders, viral diseases, and inflammatory disorders, hereditary disorders, and so on. The application also discloses pharmaceutical compositions containing these compounds, as well as synthetic methods and medical uses of the compounds.
    Type: Application
    Filed: December 24, 2021
    Publication date: July 7, 2022
    Inventors: Hongbin Li, Jian Liu, Bin Cao, Linghang Zhuang, Tongyuan Li, Suxing Liu
  • Publication number: 20220177446
    Abstract: This application discloses alkyne compounds of formula (I) useful as IRAK inhibitors and therapeutic agents for treatment of IRAK, especially IRAK-4, mediated disease or disorders, including autoimmune diseases, cancers, neurodegenerative disorders, viral diseases, and inflammatory disorders, hereditary disorders, and so on. The application also discloses pharmaceutical compositions containing these compounds, and synthetic methods and medical uses of the compounds.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 9, 2022
    Inventors: Hongbin Li, Bin Cao, Jian Liu, Linghang Zhuang, Tongyuan Li, Suxing Liu
  • Publication number: 20220169645
    Abstract: This application discloses Bruton Tyrosine Kinase (BTK) inhibitors of the general formula (IM) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of various disorders related to the excessive BTK activity, including cancers, immune disorders, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 2, 2022
    Inventors: Puhui Li, Yinfa Yan, Jian Liu, Dong Liu, Chunying Song, Suxing Liu
  • Patent number: 11332492
    Abstract: This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with CD73 activity, such as various cancers.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 17, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jian Liu, Heping Wu, Linghang Zhuang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Publication number: 20220144842
    Abstract: This application discloses compounds of formula (I) and (I?) useful as IRAK inhibitors and therapeutic agents for treatment of IRAK, especially IRAK-4, mediated disease or disorders, including autoimmune diseases, cancers, neurodegenerative disorders, viral diseases, and inflammatory disorders, hereditary disorders, and so on. The application also discloses pharmaceutical compositions containing these compounds, and synthetic methods and medical uses of the compounds.
    Type: Application
    Filed: November 4, 2021
    Publication date: May 12, 2022
    Inventors: Hongbin Li, Bin Cao, Jian Liu, Linghang Zhuang, Tongyuan Li, Suxing Liu
  • Publication number: 20220135539
    Abstract: This application discloses RAF inhibitors of the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of various disorders related to the excessive RAF activity, including cancers.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 5, 2022
    Inventors: Peng Zhao, Heping Wu, Linghang Zhuang, Yu Zhou, Suxing Liu, Jian Liu
  • Publication number: 20220056044
    Abstract: Compounds of formula (I) useful as agonists of stimulator of interferon genes (STING), the preparation method therefor, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of STING-mediated diseases or disorders are disclosed.
    Type: Application
    Filed: December 14, 2019
    Publication date: February 24, 2022
    Inventors: Dong Liu, Puhui Li, Linghang Zhuang, Fengqi Zhang, Lei Chen, Xinzhu Zhang, Chunying Song, Suxing Liu, Matthew Miller, Qiyue Hu, Yuna Yan, Jing Li, Feng He, Weikang Tao
  • Publication number: 20220009909
    Abstract: Compounds of formula (I) useful as inhibitors of ADAMTS-5 and/or ADAMTS-4, pharmaceutical compositions thereof, and use of them as therapeutic agents for the treatment of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthritis and/or rheumatoid arthritis, are disclosed.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 13, 2022
    Inventors: Dong Liu, Peng Zhao, Jian Liu, Linghang Zhuang, Xinzhu Zhang, Chunying Song, Suxing Liu
  • Publication number: 20220009910
    Abstract: This application discloses Tyk-2 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, method of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with Tyk-2 activity, such as autoimmune diseases and cancers.
    Type: Application
    Filed: July 10, 2021
    Publication date: January 13, 2022
    Inventors: Linghang Zhuang, Jian Liu, Yinfa Yan, Puhui Li, Yu Zhou, Suxing Liu
  • Publication number: 20220002267
    Abstract: Compounds of formula (I) useful as tyrosine kinase 2 (Tyk2) inhibitors, pharmaceutical compositions containing these compounds, methods of using the pharmaceutical compositions in the treatment of various disorders related to the regulation of Tyk2 activity, and methods of preparing these compounds are disclosed.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 6, 2022
    Inventors: Linghang Zhuang, Jian Liu, Heping Wu, Puhui Li, Yu Zhou, Suxing Liu
  • Publication number: 20210253621
    Abstract: This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with CD73 activity, such as various cancers.
    Type: Application
    Filed: August 28, 2019
    Publication date: August 19, 2021
    Inventors: Jian Liu, Heping Wu, Linghang Zhuang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Publication number: 20210171471
    Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.
    Type: Application
    Filed: May 3, 2019
    Publication date: June 10, 2021
    Inventors: Yinfa Yan, Minsheng Zhang, Dong Liu, Fengqi Zhang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Publication number: 20200277278
    Abstract: A deuterium atom-substituted indole formamide derivative, a preparation method therefor, and medical applications thereof. Specifically, the present invention relates to a deuterium atom-substituted indole formamide derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and uses of the derivative serving as an ROR agonist and uses of the derivative in preventing and/or treating tumors or cancers, definitions of substituent groups in general formula (I) being same as definitions in the specification.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Dong Liu, Lei Chen, Biao Lu, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Publication number: 20200131123
    Abstract: A solid dispersion, a method for preparing same, and a solid preparation comprising the solid dispersion. The solid dispersion contains (R)-4-amino-1-(1-(but-2-ynylacyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazine-7-one or a pharmaceutically acceptable salt thereof, and a carrier material. The carrier material is selected from hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose phthalate.
    Type: Application
    Filed: July 5, 2018
    Publication date: April 30, 2020
    Inventors: Dong LIU, Biao LU, Wenjian QIAN, Huaide DONG, Suxing LIU, Rumin ZHANG, Feng HE, Weikang TAO
  • Publication number: 20070219154
    Abstract: The present invention relates to methods for preventing and/or treating the growth and/or metastasis of a cell proliferative disorder. In particular, the methods include use of a protease activated receptor-1 (PAR-1) inhibitor.
    Type: Application
    Filed: December 20, 2006
    Publication date: September 20, 2007
    Inventors: Suxing Liu, Jean Lachowicz, Ho-Sam Ahn